# Research Pharmacy

> **NIH NIH P30** · SLOAN-KETTERING INST CAN RESEARCH · 2020 · $213,771

## Abstract

ABSTRACT
The Research Pharmacy (RP) Core provides a full service facility that prepares agents developed by MSK
researchers to be used as investigational drugs in preclinical or clinical studies. The Core comprises three
principal groups: the Pharmaceutical Product Facility (PPF) for drug formulation/stability and preparation; the
Clinical Grade Production (CGP) Facility for bulk product manufacturing, purification, and vialing; and the
Pharmacy Investigational Drug Service (PIDS), which provides a service to develop, procure, prepare, and
validate the preparation, packaging, and distribution of investigational drugs for clinical use. The Core services
include, but are not limited to, formulation, analysis, and evaluation of drug release rates; prediction of
interactions; and determinations of compatibility and physical stability of medications. Owing to the
infrastructure of the Core, MSK has been able to bring into early phase clinical trials multiple distinct types of
pharmacologic agents, including traditional small molecules, radiopharmaceuticals, and vaccines.
The broad range of services and collaborative work provided by the combined PPF/CGP/PIDS groups within
the RP Core has supported the research of 33 investigators from 12 Department in 37 IRB-approved protocols.
The work of the Core has contributed to 34 publications in leading general interest or cancer journals. For
example, the therapeutic antibody 3F8 is purified, manufactured, and vialed exclusively at MSK; this
therapeutic antibody forms the backbone of the Center’s research program in neuroblastoma; and has now
been validated as an effective treatment for children with refractory neuroblastoma. The Center’s large and
complex vaccine program, integrating both carbohydrate and peptide vaccines on complex KLH backbone or in
mixtures with novel adjuvants is also dependent on the services of the tripartite RP to support the clinical
testing of vaccines against cancers including serous ovarian cancer, leukemia, mesothelioma, and sarcoma.

## Key facts

- **NIH application ID:** 9858290
- **Project number:** 5P30CA008748-54
- **Recipient organization:** SLOAN-KETTERING INST CAN RESEARCH
- **Principal Investigator:** Raymond J Muller
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $213,771
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9858290

## Citation

> US National Institutes of Health, RePORTER application 9858290, Research Pharmacy (5P30CA008748-54). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/9858290. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*